recombinant human thyroid stimulating hormone for injection (rhTSH)
/ Suzhou Zelgen
- LARVOL DELTA
Home
Next
Prev
1 to 22
Of
22
Go to page
1
March 28, 2024
Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal
(clinicaltrials.gov)
- P3 | N=201 | Completed | Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Active, not recruiting ➔ Completed | Trial completion date: Jul 2024 ➔ Jul 2023 | Trial primary completion date: Jun 2024 ➔ Jul 2023
Trial completion • Trial completion date • Trial primary completion date • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Papillary Carcinoma
October 23, 2023
The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.
(clinicaltrials.gov)
- P2 | N=120 | Active, not recruiting | Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: Oct 2023 ➔ Oct 2024 | Trial primary completion date: Aug 2023 ➔ Aug 2024
Trial completion date • Trial primary completion date • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Hurthle Cell Carcinoma • Thyroid Gland Papillary Carcinoma • TG
October 23, 2023
Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer
(clinicaltrials.gov)
- P3 | N=328 | Recruiting | Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Sep 2023 ➔ Sep 2024
Trial completion date • Trial primary completion date • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Papillary Carcinoma
March 23, 2023
The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.
(clinicaltrials.gov)
- P2 | N=120 | Active, not recruiting | Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting ➔ Active, not recruiting | Trial primary completion date: Feb 2023 ➔ Aug 2023
Enrollment closed • Trial primary completion date • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Hurthle Cell Carcinoma • Thyroid Gland Papillary Carcinoma • TG
March 23, 2023
Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal
(clinicaltrials.gov)
- P3 | N=201 | Active, not recruiting | Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting ➔ Active, not recruiting | Trial completion date: Jul 2023 ➔ Jul 2024 | Trial primary completion date: Jun 2023 ➔ Jun 2024
Enrollment closed • Trial completion date • Trial primary completion date • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Papillary Carcinoma
November 29, 2022
The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.
(clinicaltrials.gov)
- P2 | N=120 | Recruiting | Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: Oct 2022 ➔ Oct 2023 | Trial primary completion date: Feb 2022 ➔ Feb 2023
Trial completion date • Trial primary completion date • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Hurthle Cell Carcinoma • Thyroid Gland Papillary Carcinoma • TG
November 29, 2022
Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer
(clinicaltrials.gov)
- P3 | N=328 | Recruiting | Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Sep 2022 ➔ Sep 2023
Trial completion date • Trial primary completion date • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Papillary Carcinoma
November 29, 2022
Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients
(clinicaltrials.gov)
- P1/2 | N=64 | Completed | Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting ➔ Completed
Trial completion • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Hurthle Cell Carcinoma • Thyroid Gland Papillary Carcinoma
July 06, 2022
Novel recombinant human thyroid-stimulating hormone in aiding postoperative assessment of patients with differentiated thyroid cancer-phase I/II study.
(PubMed, Eur J Nucl Med Mol Imaging)
- "The ZGrhTSH held the promise to be a safe and effective modality in facilitating RAI uptake and serum thyroglobulin stimulation, with better QoL of patients with DTC compared with L-T withdrawal."
Journal • P1/2 data • Endocrine Cancer • Endocrine Disorders • Oncology • Pain • Solid Tumor • Thyroid Gland Carcinoma • TG
January 12, 2022
Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal
(clinicaltrials.gov)
- P3; N=201; Recruiting; Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Papillary Carcinoma
January 12, 2022
Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer
(clinicaltrials.gov)
- P3; N=328; Recruiting; Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd; Not yet recruiting ➔ Recruiting; Initiation date: Jan 2022 ➔ Sep 2021
Clinical • Enrollment open • Trial initiation date • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Papillary Carcinoma
December 01, 2021
Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer
(clinicaltrials.gov)
- P3; N=328; Not yet recruiting; Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd; Initiation date: Aug 2021 ➔ Jan 2022
Clinical • Trial initiation date • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Papillary Carcinoma
December 01, 2021
The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.
(clinicaltrials.gov)
- P2; N=120; Recruiting; Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd; Trial completion date: Oct 2021 ➔ Oct 2022; Trial primary completion date: Sep 2021 ➔ Feb 2022
Clinical • Trial completion date • Trial primary completion date • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Hurthle Cell Carcinoma • Thyroid Gland Papillary Carcinoma • TG
December 01, 2021
Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal
(clinicaltrials.gov)
- P3; N=201; Not yet recruiting; Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd; Initiation date: Sep 2021 ➔ Dec 2021
Clinical • Trial initiation date • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Papillary Carcinoma
July 21, 2021
Safety and Efficacy of rhTSH Compared With Thyroid Hormone Withdrawal for Adjuntive Diagnostic in Patients With Differentiated Thyroid Cancer Who Have Previously Undergone Thyroidectomy
(clinicaltrials.gov)
- P3; N=201; Not yet recruiting; Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Clinical • New P3 trial • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Papillary Carcinoma
July 16, 2021
Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer
(clinicaltrials.gov)
- P3; N=328; Not yet recruiting; Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Clinical • New P3 trial • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Papillary Carcinoma
June 24, 2021
The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.
(clinicaltrials.gov)
- P2; N=120; Recruiting; Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd; Not yet recruiting ➔ Recruiting; Trial completion date: Aug 2023 ➔ Oct 2021; Trial primary completion date: Jul 2023 ➔ Sep 2021
Clinical • Enrollment open • Trial completion date • Trial primary completion date • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Hurthle Cell Carcinoma • Thyroid Gland Papillary Carcinoma • Thyroglobulin
March 26, 2021
The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.
(clinicaltrials.gov)
- P2; N=120; Not yet recruiting; Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd; Initiation date: Dec 2020 ➔ Apr 2021
Clinical • Trial initiation date • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Hurthle Cell Carcinoma • Thyroid Gland Papillary Carcinoma • Thyroglobulin
June 25, 2020
The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.
(clinicaltrials.gov)
- P2; N=120; Not yet recruiting; Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Clinical • New P2 trial • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Hurthle Cell Carcinoma • Thyroid Gland Papillary Carcinoma • Thyroglobulin
October 27, 2020
The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.
(clinicaltrials.gov)
- P2; N=120; Not yet recruiting; Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd; Trial completion date: Aug 2022 ➔ Aug 2023; Trial primary completion date: Jul 2022 ➔ Jul 2023
Clinical • Trial completion date • Trial primary completion date • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Hurthle Cell Carcinoma • Thyroid Gland Papillary Carcinoma • Thyroglobulin
December 16, 2020
Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients
(clinicaltrials.gov)
- P1/2; N=64; Recruiting; Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd; Trial completion date: Dec 2020 ➔ Dec 2022; Trial primary completion date: Oct 2020 ➔ Dec 2022
Clinical • Trial completion date • Trial primary completion date • Oncology • Solid Tumor • Thyroid Gland Anaplastic Carcinoma • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Hurthle Cell Carcinoma • Thyroid Gland Papillary Carcinoma
July 14, 2020
Clinical Study of rhTSH in the Treatment of Patients With Thyroid Cancer After Resection of Stage I/II
(clinicaltrials.gov)
- P1/2; N=64; Recruiting; Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd; Trial primary completion date: Jun 2020 ➔ Oct 2020
Clinical • Trial primary completion date • Oncology • Papillary Thyroid Cancer • Solid Tumor • Thyroid Cancer
1 to 22
Of
22
Go to page
1